Insider Buying: RxSight, Inc. (NASDAQ:RXST) Director Buys 1,443 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 1,443 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $31.18 per share, with a total value of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley purchased 11,111 shares of RxSight stock. The shares were bought at an average price of $45.37 per share, with a total value of $504,106.07.

RxSight Trading Down 2.5 %

Shares of NASDAQ:RXST opened at $30.39 on Friday. The company has a market capitalization of $1.22 billion, a PE ratio of -36.61 and a beta of 1.20. RxSight, Inc. has a twelve month low of $26.29 and a twelve month high of $66.54. The firm has a 50 day simple moving average of $38.97 and a 200-day simple moving average of $46.70.

Institutional Trading of RxSight

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after buying an additional 122,775 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of RxSight by 21.0% during the 3rd quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock worth $12,845,000 after buying an additional 45,161 shares during the last quarter. Algert Global LLC purchased a new stake in shares of RxSight during the 2nd quarter worth approximately $2,488,000. Baillie Gifford & Co. raised its position in RxSight by 17.0% in the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after purchasing an additional 60,789 shares during the last quarter. Finally, Barclays PLC raised its position in RxSight by 389.8% in the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock valued at $2,906,000 after purchasing an additional 46,783 shares during the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RXST shares. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Wells Fargo & Company dropped their price target on shares of RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Stifel Nicolaus dropped their price target on shares of RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a research report on Monday, January 13th. UBS Group started coverage on shares of RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $58.13.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.